Literature DB >> 127805

Flaujeac trait. Deficiency of human plasma kininogen.

K D Wuepper, D R Miller, M J Lacombe.   

Abstract

Flaujeac trait plasma resembled Hageman trait or Fletcher trait, in that the intrinsic coagulation pathway, plasma fibinolytic pathway, kinin-forming system, permeability factor of dilution (PF/dil) phenomenon were abnormal. The defect in each assay was reconstituted by afactor separable from Hageman factor or Fletcher factor. This substance was an alpha-globulin with an approximate mol wt of 170,000. Flaujeac plasma did not release a kinin upon incubation with kallikrein and was deficient in total kininogen antigen. Antiserum to kininogen inhibited the activity of the factor in solution. Flaufeac factor was identified as a kininogen of high molecular weight (HMW-kininogen). The mean total kininogen antigen in four children of the proposita was 51% (range 34-62%) of normal. A functional coagulation assay of HMW-kininogen in the children was 34% (range 23-55%). The results were consistent with autosomal recessive inheritance. The plasma pathways of intrinsic coagulation, fibrinolysis, kinin formation, and PF/dil generation are dependent upon HMW-kininogen. We believe this is the first demonstration of biological function for a kininogen apart from its role as a substrate for kallikreins.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 127805      PMCID: PMC333145          DOI: 10.1172/JCI108248

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  LARGE MOLECULAR SUBSTANCES AS MEDIATORS OF THE INFLAMMATORY REACTION.

Authors:  A A MILES
Journal:  Ann N Y Acad Sci       Date:  1964-08-27       Impact factor: 5.691

2.  A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.

Authors:  O D RATNOFF; J E COLOPY
Journal:  J Clin Invest       Date:  1955-04       Impact factor: 14.808

3.  Effect of surface and Hageman factor on the endogenous or spontaneous activation of the fibrinolytic system.

Authors:  S G IATRIDIS; J H FERGUSON
Journal:  Thromb Diath Haemorrh       Date:  1961-12-15

4.  Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation.

Authors:  J MARGOLIS
Journal:  J Physiol       Date:  1958-11-10       Impact factor: 5.182

5.  [Role of the contact factor (Hageman factor) in fibrinolysis].

Authors:  S NIEWIAROWSKI; O PROU-WARTELLE
Journal:  Thromb Diath Haemorrh       Date:  1959-09-01

6.  Susceptibility of the guinea pig to pharmacological factors from its own serum.

Authors:  M E MACKAY; A A MILES; M SCHACHTER; D L WILHELM
Journal:  Nature       Date:  1953-10-17       Impact factor: 49.962

7.  Separation of 2 different substrates for plasma kinin-forming enzymes.

Authors:  S Jacobsen
Journal:  Nature       Date:  1966-04-02       Impact factor: 49.962

8.  Preparation, characterization, and activation of a highly purified factor XI: evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII.

Authors:  S Schiffman; P Lee
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

9.  Partial purification and some properties of high molecular weight kininogen, bovine kininogen-I.

Authors:  M Yano; S Nagasawa; T Suzuki
Journal:  J Biochem       Date:  1971-03       Impact factor: 3.387

10.  Bovine plasma kininogens. I. Further purification of high molecular weight kininogen and its physicochemical properties.

Authors:  M Komiya; H Kato; T Suzuki
Journal:  J Biochem       Date:  1974-10       Impact factor: 3.387

View more
  34 in total

1.  Turnover of human and monkey plasma kininogens in rhesus monkeys.

Authors:  T Yamada; D A Wing; J V Pierce; G W Pettit
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

2.  Purification of high molecular weight kininogen and the role of this agent in blood coagulation.

Authors:  H Saito
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

3.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 4.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

5.  Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen.

Authors:  R T Matheson; D R Miller; M J Lacombe; Y N Han; S Iwanaga; H Kato; K D wuepper
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

6.  Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma.

Authors:  V H Donaldson; J Kleniewski; H Saito; J K Sayed
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

7.  Potentiation of the function of Hageman factor fragments by high molecular weight kininogen.

Authors:  C Y Liu; C F Scott; A Bagdasarian; J V Pierce; A P Kaplan; R W Colman
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

8.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

9.  Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens.

Authors:  M Maier; K F Austen; J Spragg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

10.  Rapid purification of human high molecular weight kininogen.

Authors:  F M Habal; H Z Movat
Journal:  Agents Actions       Date:  1976-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.